Back to today’s briefing

Story perspectives

Scribe Therapeutics Cuts 20% Workforce to Focus on Cardio Pipeline

1/9/2025

50 9

Summary

Story summary

Scribe Therapeutics has made the tough decision to cut nearly 20% of its workforce, redirecting its efforts toward advancing its cardiometabolic pipeline. This strategic shift comes on the heels of encouraging primate data for its gene silencer STX1150. Co-founded by Nobel laureate Jennifer Doudna, the company is also forging strong partnerships with leading pharmaceutical giants.

1 of 1

Story summary

Scribe Therapeutics has made the tough decision to cut nearly 20% of its workforce, redirecting its efforts toward advancing its cardiometabolic pipeline. This strategic shift comes on the heels of encouraging primate data for its gene silencer STX1150. Co-founded by Nobel laureate Jennifer Doudna, the company is also forging strong partnerships with leading pharmaceutical giants.